Background and AimsMetabolic dysfunction‐associated steatotic liver disease (MASLD) is responsible for a significant global health burden. Despite this burden, the prevalence and mortality of MASLD‐related cirrhosis remain inadequately defined, hindering effective public health strategies. This study aimed to estimate the global prevalence and mortality associated with MASLD‐related cirrhosis.MethodsA systematic search of PubMed, Ovid MEDLINE, EMBASE, Web of Science and SCOPUS was conducted using keywords related to MASLD and cirrhosis from inception of each database used through June 2024. COVIDENCE was used for abstract and manuscript review. MASLD populations were categorised into ‘general practice setting’ and ‘high risk setting’, which indicated studies from inpatient setting or those referred for liver biopsy for an indication (elevated liver enzymes). Our data extraction and quality assessment followed PRISMA guidelines. A random‐effects model was utilised for meta‐analysis.ResultsFrom 7924 identified articles, 35 studies comprising 513,742 patients with MASLD met the inclusion criteria. The pooled global prevalence of cirrhosis among MASLD patients was 3.26% (95% CI: 2.47%–4.31%) in general practice settings (4 studies) and 14.51% (95% CI: 11.22%–18.57%) among those in inpatient settings or referred for liver biopsy (31 studies). Regionally, higher prevalence rates in high‐risk settings were observed in North America and Australia (18.38%; 95% CI: 9.06%–33.75%), followed by Europe (10.16%; 95% CI: 5.71%–17.44%) and Asia (9.12%; 95% CI: 6.11%–13.40%) (p = 0.007). Notably, ICD‐based diagnoses indicated a significantly higher prevalence of cirrhosis (27.43%) compared to those diagnosed by liver biopsy (13.24%; p < 0.001). The pooled all‐cause mortality rate for MASLD‐cirrhosis patients was estimated at 7.91 per 100 person‐years (95% CI: 4.44–13.71) (9 studies).ConclusionsThis meta‐analysis underscores the substantial prevalence of cirrhosis among MASLD patients and highlights significant geographic and demographic variability, calling for improved screening and management strategies.

中文翻译：

---

Meta 分析：代谢功能障碍相关脂肪性肝病中肝硬化的全球患病率和死亡率


代谢功能障碍相关脂肪性肝病 （MASLD） 造成了巨大的全球健康负担。尽管有这种负担，但 MASLD 相关肝硬化的患病率和死亡率仍未明确，阻碍了有效的公共卫生策略。本研究旨在估计与 MASLD 相关肝硬化相关的全球患病率和死亡率。